• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is AbbVie (ABBV) Reasonably Priced After Its Pipeline Progress?

    Simply Wall St·10/10/2026 01:24:06
    语音播报

    AbbVie has turned into a powerful long term winner for shareholders. With the stock now around US$276, the key issue is whether those cash flows can support the current valuation. After a string of upbeat clinical and regulatory headlines, the central question is how much of the future cash generation story is already reflected in today’s price.

    • Over the past 5 years the share price has gained about 200%, which puts a lot of weight on how durable AbbVie’s future cash flows prove to be.
    • Positive trial results for epcoritamab in lymphoma and new approvals and designations across oncology, neurology and dermatology can support expectations for longer running and more diversified cash flows from AbbVie’s pipeline as older drugs face patent pressure.
    • Prefer to judge AbbVie on earnings? See why AbbVie's 77.9x P/E tells a different valuation story.

    For investors, the debate is whether AbbVie’s current share price is adequately supported by the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate.

    To see how this same cash flow question plays out across other established healthcare names, scan through 34 healthcare AI stocks.

    Is AbbVie a Bargain on Cash Flow?

    The Discounted Cash Flow (DCF) model here focuses on the cash AbbVie can return to shareholders over time. Latest twelve month free cash flow sits at about $18.3b, and the model assumes these cash flows grow from this base rather than shrink. Ten year projections rise into the low to mid $40b range by the early 2030s, which implies the business keeps generating large absolute cash sums even as older therapies face more competition.

    Those assumptions matter because the current share price of $276.47 already embeds a lot of optimism about AbbVie’s ability to replace expiring products with new ones. Positive Phase 3 data for epcoritamab in frontline diffuse large B cell lymphoma supports the idea of a pipeline that can help sustain those future cash flows. This aligns with the Discounted Cash Flow (DCF) result that puts intrinsic value substantially above the current price. Find out what AbbVie could be worth using our Discounted Cash Flow (DCF) estimate.

    The AbbVie Narrative: What Would Justify Today's Price?

    Simply Wall St Narratives picks up where AbbVie’s valuation puzzle leaves off. Narratives spell out which paths for AbbVie’s growth, margins and earnings would need to play out for the stock to be worth materially more or materially less than today’s price, and they sit on Simply Wall St’s Community page. Rather than rely on a single multiple or model output, each one lays out the assumptions behind its fair value so you can compare them with future results as they arrive.

    One of the top community narratives on AbbVie: roughly fairly valued

    "The key requirement for AbbVie is successfully executing on its pipeline and business development so that new immunology, oncology and neuroscience drugs replace revenue from declining products…"

    Discover why this Narrative puts AbbVie at roughly fairly valued.

    AbbVie’s valuation story leaves one crucial angle unresolved

    For a business as large and complex as AbbVie, the people choosing where to allocate capital and how they are rewarded can matter as much as any DCF model. See who runs AbbVie and how they are paid.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.